O
OPM / 奥浦迈
Shanghai STAR-listed serum-free media + biologics CDMO (688293)
About OPM / 奥浦迈
Shanghai STAR-listed serum-free cell-culture media + biologics CDMO OEM (OPM / 奥浦迈; STAR 688293) offering CHO/HEK293/Vero media and feed platforms plus antibody/protein CDMO for biopharma manufacturers. Founded in 2013 with Shanghai Pudong International Medical Park / Ziping Rd HQ narrative and roughly 367 employees STAR-filing class. Primary Dealroom domain remains opmbiosciences.com (soft-skip force-overwrite of CN apex opmbio.com twin). Mid-size China cell-culture media leftover peer beyond Bio-Engine; soft-skip ExCell mandate and Tianhang·Procell·BasalMedia size peers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- China
- Listing
- IPO 2022
- Sector
- Biotech & Life Sciences
- Outcome tier
- Colt$25–100M revenue
News
Open roles
OPM / 奥浦迈 in its local ecosystem
The OPM / 奥浦迈 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- FCFortune Capital
- CIChina Life Private Equity Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about OPM / 奥浦迈 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OPM / 奥浦迈 on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

